cabergoline has been researched along with paricalcitol in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Ciebiera, M; Jakiel, G; Męczekalski, B; Słabuszewska-Jóźwiak, A; Wojtyła, C; Łukaszuk, K | 1 |
2 review(s) available for cabergoline and paricalcitol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Cabergoline; Catechin; Ergocalciferols; Ergolines; Female; Humans; Hydrocarbons, Fluorinated; Leiomyoma; Pyrimidines; Quality of Life; Uterine Neoplasms; Vitamin D | 2017 |